Financial Perspectives’s Regeneron Pharmaceuticals REGN Stock Holding History

Financial Perspectives’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$119K	Hold	191	–	–	0.03%	227
2026 Q1	$148K	Sell	191 -2	-1%	-$1.53K	0.04%	196
2025 Q4	$149K	Hold	193	–	–	0.04%	188
2025 Q3	$109K	Hold	193	–	–	0.03%	223
2025 Q2	$101K	Hold	193	–	–	0.03%	219
2025 Q1	$122K	Hold	193	–	–	0.04%	192
2024 Q4	$137K	Buy	193 +19	+11%	+$15.9K	0.05%	177
2024 Q3	$183K	Hold	174	–	–	0.06%	146
2024 Q2	$183K	Hold	174	–	–	0.07%	142
2024 Q1	$167K	Hold	174	–	–	0.06%	151
2023 Q4	$153K	Hold	174	–	–	0.06%	158
2023 Q3	$143K	Hold	174	–	–	0.07%	153
2023 Q2	$125K	Hold	174	–	–	0.06%	160
2023 Q1	$143K	Hold	174	–	–	0.07%	147
2022 Q4	$126K	Hold	174	–	–	0.06%	154
2022 Q3	$120K	Hold	174	–	–	0.07%	155
2022 Q2	$103K	Hold	174	–	–	0.06%	168
2022 Q1	$122K	Hold	174	–	–	0.06%	169
2021 Q4	$110K	Hold	174	–	–	0.05%	166
2021 Q3	$105K	Hold	174	–	–	0.05%	169
2021 Q2	$97.2K	Hold	174	–	–	0.05%	189
2021 Q1	$82.3K	Hold	174	–	–	0.04%	191
2020 Q4	$84.1K	Buy	174 +94	+118%	+$50.7K	0.05%	182
2020 Q3	$44.8K	Buy	80 +12	+18%	+$7.28K	0.03%	209
2020 Q2	$42.4K	Hold	68	–	–	0.03%	198
2020 Q1	$33.2K	Buy	+68	New	+$28K	0.03%	194

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Financial Perspectives's REGN Position: Q2 2026 in Review

Financial Perspectives held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 191 shares worth $119K. The position accounts for 0.03% of the portfolio, ranked #227.

Financial Perspectives first reported a position in REGN in Q1 2020 and has held it in 26 quarters since. The position peaked at $183K in Q3 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Financial Perspectives held 191 shares of Regeneron Pharmaceuticals worth $119K as of Q2 2026.
Financial Perspectives left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 0.03% of Financial Perspectives's portfolio in Q2 2026, its #227 holding.
Financial Perspectives first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
Financial Perspectives's Regeneron Pharmaceuticals position peaked at $183K in Q3 2024.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Financial Perspectives's 13F filing for Q2 2026, filed 24 Jul 2026.